Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 12, 2020

SELL
$29.6 - $43.71 $4.07 Million - $6 Million
-137,343 Closed
0 $0
Q3 2019

Nov 13, 2019

SELL
$29.87 - $42.22 $5.85 Million - $8.27 Million
-195,874 Reduced 58.78%
137,343 $4.24 Million
Q2 2019

Aug 12, 2019

BUY
$31.16 - $39.46 $10.4 Million - $13.1 Million
333,217 New
333,217 $13.1 Million

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Global Endowment Management, LP Portfolio

Follow Global Endowment Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Global Endowment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Global Endowment Management, LP with notifications on news.